| SCHEDULE OF RECONCILIATION OF PROFIT (LOSS) FROM SEGMENTS TO CONSOLIDATED |
The
following table presents reportable segment profit and loss, including significant expense categories, attributable to the Company’s
reportable segment for the periods presented:
SCHEDULE
OF RECONCILIATION OF PROFIT (LOSS) FROM SEGMENTS TO CONSOLIDATED
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
For The Three Months |
|
|
For The Six Months |
|
| |
|
Ended June 30, |
|
|
Ended June 30, |
|
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue, net: |
|
$ |
9,232 |
|
|
$ |
12,042 |
|
|
$ |
20,747 |
|
|
$ |
22,219 |
|
| Less: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cost of revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fixed |
|
|
1,694 |
|
|
|
1,619 |
|
|
|
3,384 |
|
|
|
3,197 |
|
| Variable |
|
|
2,262 |
|
|
|
2,617 |
|
|
|
4,717 |
|
|
|
4,905 |
|
| Operating and other expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sales and marketing |
|
|
2,910 |
|
|
|
2,887 |
|
|
|
5,723 |
|
|
|
5,707 |
|
| Research and development |
|
|
173 |
|
|
|
146 |
|
|
|
350 |
|
|
|
283 |
|
| General and administrative |
|
|
2,661 |
|
|
|
2,141 |
|
|
|
5,211 |
|
|
|
4,381 |
|
| Interest & other expense, net |
|
|
65 |
|
|
|
117 |
|
|
|
123 |
|
|
|
415 |
|
| Provision for income taxes |
|
|
- |
|
|
|
4 |
|
|
|
18 |
|
|
|
8 |
|
| Segment net (loss) income |
|
|
(533 |
) |
|
|
2,511 |
|
|
|
1,221 |
|
|
|
3,323 |
|
| Reconciliation of profit or loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss on discontinued operations |
|
|
(107 |
) |
|
|
(74 |
) |
|
|
(214 |
) |
|
|
(178 |
) |
| Consolidated net (loss) income |
|
$ |
(640 |
) |
|
$ |
2,437 |
|
|
$ |
1,007 |
|
|
$ |
3,145 |
|
|
| SCHEDULE OF RECONCILIATION OF ADJUSTED EBITDA |
SCHEDULE
OF RECONCILIATION OF ADJUSTED EBITDA
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Three Months Ended |
|
|
Six Months Ended |
|
| |
|
June 30, |
|
|
June 30, |
|
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| (Loss) income from continuing operations (GAAP Basis) |
|
$ |
(533 |
) |
|
$ |
2,511 |
|
|
$ |
1,221 |
|
|
$ |
3,323 |
|
| Depreciation and amortization |
|
|
101 |
|
|
|
67 |
|
|
|
196 |
|
|
|
119 |
|
| Stock-based compensation |
|
|
9 |
|
|
|
53 |
|
|
|
24 |
|
|
|
132 |
|
| Severance & related expense |
|
|
524 |
|
|
|
- |
|
|
|
692 |
|
|
|
- |
|
| Asset impairment - lab supplies |
|
|
198 |
|
|
|
- |
|
|
|
198 |
|
|
|
- |
|
| Taxes expense |
|
|
- |
|
|
|
4 |
|
|
|
18 |
|
|
|
8 |
|
| Interest accretion expense |
|
|
- |
|
|
|
12 |
|
|
|
- |
|
|
|
30 |
|
| Note payable interest |
|
|
49 |
|
|
|
176 |
|
|
|
127 |
|
|
|
373 |
|
| Other expense/income, net |
|
|
10 |
|
|
|
(14 |
) |
|
|
14 |
|
|
|
(29 |
) |
| Change in fair value of note payable |
|
|
7 |
|
|
|
(57 |
) |
|
|
(18 |
) |
|
|
41 |
|
| Adjusted EBITDA |
|
$ |
365 |
|
|
$ |
2,752 |
|
|
$ |
2,472 |
|
|
$ |
3,997 |
|
|